H.C. Wainwright raised the firm’s price target on Avalo Therapeutics (AVTX) to $25 from $15 and keeps a Buy rating on the shares. AbbVie’s (ABBV) latest hidradenitis suppurativa data validates IL-1 but caps efficacy at 45%-50% HiSCR75, positioning AVTX-009 for success, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data
- 3 Best Stocks to Buy Now, 9/12/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 9/5/2025, According to Top Analysts
- Buy Rating for Avalo Therapeutics Driven by Promising AVTX-009 Development and Market Potential
- Avalo Therapeutics initiated with a Buy at TD Cowen